Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status

Cancer Research

Volumn 68, Issue 8, 2008, Pages 2831-2840

  Hu, Chun Mei ^a   Chang, Zee Fen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; THYMIDINE TRIPHOSPHATE; THYMIDYLATE SYNTHASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL STRAIN HCT116; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DNA DAMAGE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LETHALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA DAMAGE; DOXORUBICIN; GENE SILENCING; GENETIC VECTORS; HUMANS; LENTIVIRUS; NUCLEOSIDE-PHOSPHATE KINASE; RNA, CATALYTIC; RNA, SMALL INTERFERING; RNA, VIRAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42349114776     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3069     Document Type: Article

References (34)

1. Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem 1988;57:349-74.
2. Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995;67:155-86.
3. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
4. Mader RM, Muller M, Steger GG. Resistance to 5-fluorouracil. Gen Pharmacol 1998;31:661-6.
5. Grem JL, Danenberg KD, Behan K, et al. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin Cancer Res 2001;7:999-1009.
6. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 1999;80:1726-33.
7. +-enriched peripheral blood progenitor cells. Cancer Gene Ther 2001;8:966-73.
8. Rose MG, Farrell MP, Schmitz JC. Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer 2002;1:220-9.
9. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
10. Allegra C. Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol 2002;20:1711-3.
11. Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241-50.
12. Giovannetti E, Backus HH, Wouters D, et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007;96:769-75.
13. Meyers M, Hwang A, Wagner MW, et al. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 2003;22:7376-88.
14. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
15. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
16. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
17. Lee LS, Cheng Y. Human thymidylate kinase. Purification, characterization, and kinetic behavior of the thymidylate kinase derived from chronic myelocytic leukemia. J Biol Chem 1977;252:5686-91.
18. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
19. An DS, Qin FX, Auyeung VC, et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006;14:494-504.
20. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cycle 2006;5:2103-9.
21. Liu Y, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood 2006;107:3027-33.
22. Carter SK. Adriamycin - a review. J Natl Cancer Inst 1975;55:1265-74.
23. Chang ZF, Huang DY, Hsue NC. Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells. J Biol Chem 1994;269:21249-54.
24. Ke PY, Kuo YY, Hu CM, Chang ZF. Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability. Genes Dev 2005;19:1920-33.
25. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3:207-12.
26. Sherman PA, Fyfe JA. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem 1989;180:222-6.
27. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
28. Lowndes NF, Toh GW. DNA repair: the importance of phosphorylating histone H2AX. Curr Biol 2005;15:R99-102.
29. Schmitz JC, Chen TM, Chu E. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res 2004;64:1431-5.
30. Longley DB, Boyer J, Allen WL, et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 2002;62:2644-9.
31. Goulian M, Bleile B, Tseng BY. The effect of methotrexate on levels of dUTP in animal cells. J Biol Chem 1980;255:10630-7.
32. Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003;22:5792-812.
33. Shiloh Y. ATM and related protein kinases: safe-guarding genome integrity. Nat Rev Cancer 2003;3:155-68.
34. Berkovich E, Monnat RJ, Jr., Kastan MB. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 2007;9:683-90.